Business Description
ME Therapeutics Holding Inc
NAICS : 541714
SIC : 3741
ISIN : CA5527671054
Description
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 33.68 | |||||
| Equity-to-Asset | 1 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.96 | |||||
| 9-Day RSI | 63.56 | |||||
| 14-Day RSI | 62.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -989.01 | |||||
| ROA % | -880.3 | |||||
| ROIC % | -3804.08 | |||||
| ROC (Joel Greenblatt) % | -51318.52 | |||||
| ROCE % | -988.66 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 67.41 | |||||
| Price-to-Tangible-Book | 66 | |||||
| EV-to-EBIT | -14.35 | |||||
| EV-to-EBITDA | -14.35 | |||||
| EV-to-FCF | -160.37 | |||||
| Earnings Yield (Greenblatt) % | -6.97 | |||||
| FCF Yield % | -0.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ME Therapeutics Holding Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.296 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 62.57 | ||
| 14-Day ATR (C$) | 0.142057 | ||
| 20-Day SMA (C$) | 3.6825 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (C$) | 0.05 - 7 | ||
| Shares Outstanding (Mil) | 25.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ME Therapeutics Holding Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ME Therapeutics Holding Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
ME Therapeutics Holding Inc Frequently Asked Questions
What is ME Therapeutics Holding Inc(XCNQ:METX)'s stock price today?
The current price of XCNQ:METX is C$3.96. The 52 week high of XCNQ:METX is C$7.00 and 52 week low is C$0.05.
When is next earnings date of ME Therapeutics Holding Inc(XCNQ:METX)?
The next earnings date of ME Therapeutics Holding Inc(XCNQ:METX) is .
Does ME Therapeutics Holding Inc(XCNQ:METX) pay dividends? If so, how much?
ME Therapeutics Holding Inc(XCNQ:METX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers